To access this element change to forms mode OFF
Grant Award View - GA301398
A novel probiotic as a preventive strategy for colorectal neoplasia
GA ID:
GA301398
Agency:
Cancer Australia
Approval Date:
4-May-2023
Publish Date:
23-May-2023
Category:
Cancer
Grant Term:
1-Jun-2023 to 31-May-2026
Value (AUD):
$596,769.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 22/23 Improved cancer control
Grant Program:
2022 Priority-driven Collaborative Cancer Research Scheme (PdCCRS)
Grant Activity:
A novel probiotic as a preventive strategy for colorectal neoplasia
Purpose:
Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth most common cancer in Australia. Current preventive strategies against CRC are not suitable for all patients and there is an unmet clinical need.
This research will prove that beneficial bacteria exist in our gut, and will test if and how these bacteria prevent CRC in pre-clinical models. The research outcome will lay a foundation for future clinical trials on using these bacteria as probiotics for preventing CRC.
GO ID:
GO Title:
2022 Priority-driven Collaborative Cancer Research Scheme for funding commencing 2023
Internal Reference ID:
2020405_Yim
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Kensington
Town/City:
Sydney
Postcode:
2052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
Country:
AUSTRALIA